ArticleThe New England journal of medicine2016
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06398977 (Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.Frontiers in immunology · 2023Pooled it
- Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms.Precision clinical medicine · 2025Trial
- Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study.Annals of medicine · 2026Article
- Empagliflozin alleviates lipid deposition and inflammation in diabetic kidney disease by downregulating C1QC.Molecular and cellular biochemistry · 2026Article
- Imidazole Propionate Induces Kidney Damage by Activating the ROS-NLRP3 Signaling Pathway Through mTOR Inhibition of Autophagy in Renal Tubular Epithelial Cells.Mediators of inflammation · 2026Article
- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Acute Kidney Injury Post Off-Pump Coronary Artery Bypass Grafting: A Retrospective Cohort Study and Meta-Analysis.Reviews in cardiovascular medicine · 2026Article
- Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i.Renal failure · 2025Review
- Benefits of Sodium-Glucose Cotransporter-2 Inhibitors with Renin-Angiotensin System Blockers in Type-2 Diabetes: A Cohort Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.Diabetes, obesity & metabolism · 2025Article
- Article
- SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges.Frontiers in immunology · 2025Review
- Integrating network analysis and experimental validation to reveal the ferroptosis-associated mechanism of acteoside in the treatment of diabetic nephropathy.Frontiers in pharmacology · 2025Article
- Mitochondrial Pathophysiology on Chronic Kidney Disease.International journal of molecular sciences · 2022Review
- Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice.International journal of molecular sciences · 2021Article
- Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects.Diagnostics (Basel, Switzerland) · 2021Review
- Revealing active components, action targets and molecular mechanism of Gandi capsule for treating diabetic nephropathy based on network pharmacology strategy.BMC complementary medicine and therapies · 2020Article
- Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice.International journal of biological sciences · 2020Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
28106974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.